Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Evrópusambandið - íslenska - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant inflúensu veira (lifandi, bæklaða) eftir álag: a/víetnam/1203/2004 (h5n1) álag - inflúensu, manna - bóluefni - fyrirbyggjandi inflúensu í opinberlega lýst faraldur ástandið í börn og unglingar frá 12 mánuði til að minna en 18 ára aldri. faraldur inflúensu h5n1 astrazeneca ætti að vera notuð í samræmi við opinbera leiðsögn.

Tremelimumab AstraZeneca Evrópusambandið - íslenska - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) Evrópusambandið - íslenska - EMA (European Medicines Agency)

vaxzevria (previously covid-19 vaccine astrazeneca)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - bóluefni - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Enrylaze Evrópusambandið - íslenska - EMA (European Medicines Agency)

enrylaze

jazz pharmaceuticals ireland limited - crisantaspase - forvarnarfrumuæxli-eitilfrumuhvítblæði - Æxlishemjandi lyf - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

Koselugo Evrópusambandið - íslenska - EMA (European Medicines Agency)

koselugo

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - Æxlishemjandi lyf - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Pulmicort Turbuhaler Innöndunarduft 100 míkróg/skammt Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pulmicort turbuhaler innöndunarduft 100 míkróg/skammt

astrazeneca a/s - budesonidum inn - innöndunarduft - 100 míkróg/skammt

Pulmicort Turbuhaler Innöndunarduft 200 míkróg/skammt Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pulmicort turbuhaler innöndunarduft 200 míkróg/skammt

astrazeneca a/s - budesonidum inn - innöndunarduft - 200 míkróg/skammt

Pulmicort Turbuhaler Innöndunarduft 400 míkróg/skammt Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pulmicort turbuhaler innöndunarduft 400 míkróg/skammt

astrazeneca a/s - budesonidum inn - innöndunarduft - 400 míkróg/skammt

Lumoxiti Evrópusambandið - íslenska - EMA (European Medicines Agency)

lumoxiti

astrazeneca ab - moxetumomab pasudotox - hvítblæði, hairy cell - Æxlishemjandi lyf - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Zoladex Vefjalyf 10,8 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zoladex vefjalyf 10,8 mg

astrazeneca ab - goserelinum acetat - vefjalyf - 10,8 mg